Update on Fused Capromab Pendetide Imaging of Prostate Cancer

Sodee, D. Bruce; Nelson, A.D.; Faulhaber, Peter; MacLennan, Gregory T.; Resnick, Martin I.; Bakale, G.

doi:10.3816/cgc.2005.n.004

Cited by 34 publications

(21 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In-capromab pendetide. Patients underwent imaging without fasting by using a protocol similar to that used by Soddee and co-workers ( 21 In-capromab pendetide, with sensitivities of 100% (10 of 10 patients; 95% CI: 69%, 100%) and 10% (one of 10 patients; 95% CI: 0%, 45%), respectively ( P = .003). Figure 3 and Table 3 summarize data and reference standards applied for extraprostatic disease.…”

Section: F-facbc Imaging Protocolmentioning

confidence: 99%

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Schuster

Savir-Baruch²,

Nieh³

et al. 2011

Radiology

139

130

View full text Add to dashboard Cite

Purpose:To compare the diagnostic performance of the synthetic amino acid analog radiotracer anti -1-amino-3-fl uorine 18-fl uorocyclobutane-1-carboxylic acid ( anti -3-18 F-FACBC) with that of indium 111 ( 111 In)-capromab pendetide in the detection of recurrent prostate carcinoma. Materials andMethods:This prospective study was approved by the institutional review board and complied with HIPAA guidelines. Written informed consent was obtained. In-capromab pendetide single photon emission computed tomography (SPECT)/CT were performed within 6 weeks of each other. Studies were evaluated by two experienced interpreters for abnormal uptake suspicious for recurrent disease in the prostate bed and extraprostatic locations. The reference standard was a combination of tissue correlation , imaging, laboratory, and clinical data. Diagnostic performance measures were calculated and tests of the statistical signifi cance of differences determined by using the McNemar x 2 test as well as approximate tests based on the difference between two proportions. Results:For disease detection in the prostate bed, anti -3-18 F-FACBC had a sensitivity of 89 % (32 of 36 patients; 95% confi dence interval [CI]: 74%, 97%), specifi city of 67% (eight of 12 patients; 95% CI: 35%, 90%), and accuracy of 83% (40 of 48 patients; 95% CI: 70%, 93%).111 In-capromab pendetide had a sensitivity of 69% (25 of 36 patients; 95% CI: 52%, 84%), specifi city of 58% (seven of 12 patients; 95% CI: 28%, 85%), and accuracy of 67% (32 of 48 patients; 95% CI: 52%, 80%). In the detection of extraprostatic recurrence, anti -3-18 F-FACBC had a sensitivity of 100% (10 of 10 patients; 95% CI: 69%, 100%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 100% (17 of 17 patients; 95% CI: 80%, 100%).111 In-capromab pendetide had a sensitivity of 10% (one of 10 patients; 95% CI: 0%, 45%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 47% (eight of 17 patients; 95% CI: 23%, 72%). Conclusion:anti -3-18 F-FACBC PET/CT was more sensitive than 111 Incapromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.

show abstract

Section: F-facbc Imaging Protocolmentioning

confidence: 99%

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Schuster

Savir-Baruch²,

Nieh³

et al. 2011

Radiology

139

130

View full text Add to dashboard Cite

show abstract

“…This technology was initially developed to aid nuclear medicine physicians in scan interpretation. Early results from a multi-institutional study 59 indicate that fusion techniques can significantly enhance the detection of nodal disease, eliminate some of the false positive results from bowel activity, and accurately map the prostate gland for tumor distribution. Because of these results, it is now recommended that all RIS studies be performed with either CT or MRI fusion.…”

Section: Discussion/future Directionsmentioning

confidence: 99%

The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients

Jani¹,

Liauw²,

Blend³

2007

Clinical Medicine & Research

View full text Add to dashboard Cite

Indium-111 radioimmunoscintigraphy (RIS) has an increasing role in the treatment of prostate cancer and is most commonly performed at this disease site using labeled monoclonal antibody against prostate-specific membrane antigen. There are many limitations of RIS, including low spatial resolution, low diagnostic yield and limited availability. Despite these limitations, the efficacy of RIS has been demonstrated in many clinical studies, including multi-institutional investigations. The highest sensitivity and specificity of RIS appears to be in the post-radical retropubic prostatectomy (post-RRP) setting. RIS has recently been explored for its role in clinical radiotherapy decision-making, and was found to have a significant impact in selecting patients for radiotherapy and for the general radiotherapy treatment volume definition. RIS has also recently been explored for its role in radiotherapy planning and was found to impact clinical target volume design. However, manual editing of the RIS volume is still necessary when projected into the radiotherapy-planning scan, as there is often overlap in the RIS-defined uptake regions with normal structures (rectum, bladder and symphysis bone marrow). The impact of RIS on biochemical control has been explored, with studies in this area yielding conflicting results. It appears that the maximum impact of RIS is possible when areas of labeled antibody uptake regions are co-registered with the radiotherapy-planning computed tomography scan.The larger RIS-guided target volumes do not appear to be prohibitive in increasing radiotherapy-related toxicity. Future directions of the use of RIS for post-RRP prostate cancer are discussed.

show abstract

“…162,163) or suspected recurrent prostate cancer after prostatectomy. In a large clinical trial, the advantages derived primarily from detection of soft tissue and especially lymph node metastases (164). Nevertheless, the benefits of this technique remain controversial, as bone metastases are the primary cause of morbidity and mortality, and these lesions are more accurately detected by bone scanning.…”

Section: Clinical Applications Of Imaging Probesmentioning

confidence: 99%

“…Nevertheless, the benefits of this technique remain controversial, as bone metastases are the primary cause of morbidity and mortality, and these lesions are more accurately detected by bone scanning. The imaging technique is difficult to perform, and fusion imaging of the capromab pendetide single photon emission CT with CT or MRI is a highly valuable adjunct (164). In addition, it has been reported that capromab pendetide lacks utility for predicting response to salvage radiation therapy (165).…”

Section: Clinical Applications Of Imaging Probesmentioning

confidence: 99%

The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development

Kelloff

Krohn

Larson

et al. 2005

Clinical Cancer Research

203

142

View full text Add to dashboard Cite

As addressed by the recent Food and Drug Administration Critical Path Initiative, tools are urgently needed to increase the speed, efficiency, and cost-effectiveness of drug development for cancer and other diseases. Molecular imaging probes developed based on recent scientific advances have great potential as oncologic drug development tools. Basic science studies using molecular imaging probes can help to identify and characterize disease-specific targets for oncologic drug therapy. Imaging end points, based on these disease-specific biomarkers, hold great promise to better define, stratify, and enrich study groups and to provide direct biological measures of response. Imaging-based biomarkers also have promise for speeding drug evaluation by supplementing or replacing preclinical and clinical pharmacokinetic and pharmacodynamic evaluations, including target interaction and modulation. Such analyses may be particularly valuable in early comparative studies among candidates designed to interact with the same molecular target. Finally, as response biomarkers, imaging end points that characterize tumor vitality, growth, or apoptosis can also serve as early surrogates of therapy success. This article outlines the scientific basis of oncology imaging probes and presents examples of probes that could facilitate progress. The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes. Value of Imaging-Based Biomarkers in Drug DevelopmentIn the last 10 years, novel treatments have been developed that prolong survival, induce remission, and provide better quality of life for cancer patients. Among the successes are the molecularly targeted cancer treatment drugs, notably the anti-HER-2/neu antibody trastuzumab for ErbB2-expressing breast cancers (1) and the kinase inhibitor imatinib for chronic myelogenous leukemia and gastrointestinal stromal tumors (2). In addition, molecularly targeted drugs have shown efficacy in lung cancer [e.g., the epidermal growth factor receptor (EGFR) inhibitor erlotinib; ref. 3], multiple myeloma (e.g., the proteasome inhibitor bortezomib; ref. 4), advanced colorectal cancer (e.g., the EGFR antibody cetuximab; refs. 5, 6), and other breast cancer settings (e.g., the aromatase inhibitor letrozole for hormone receptor -unknown or hormone receptor -positive locally advanced or metastatic breast cancer in postmenopausal women; ref. 7). Despite their efficacy in certain settings, molecularly targeted drugs are resource-intensive to develop, with the considerable expenditures, protracted time, and numerous patients required during development resulting in high costs of the approved therapy (8). Moreover, molecular targets have been identified and characterized in relatively few oncology patients; improved phenotypic characterization of the underlying molecular lesions would expand the overall effect of targeted agents in onc...

show abstract

Update on Fused Capromab Pendetide Imaging of Prostate Cancer

Cited by 34 publications

References 52 publications

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients

The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development

Contact Info

Product

Resources

About

Update on Fused Capromab Pendetide Imaging of Prostate Cancer

Cited by 34 publications

References 52 publications

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients

The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development

Contact Info

Product

Resources

About

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT